A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）

Recruiting now

Conditions studied: Drug-induced Liver Injury

In brief

This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.

Key facts

Study ID

NCT02961413

Run by

Drug Induced Liver Disease Study Group

People needed

10000

Starts

2016-04-01

Expected to finish

2030-12-01

Last updated by the study team

2025-05-04

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of DILI patients with various types and severity according to the 2015 version of the Chinese DILI treatment guidelines
• RUCAM ≥6, or RUCAM between 3-5 is required by the three experts determined that the drug-induced liver injury
• patient can provide informed consent form

You may not qualify if…

• non-drug-induced liver injury

Where it is running

• Renji hospital — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.